884510-86-5Relevant articles and documents
A convergent preparation of the CHK1 inhibitor MK-8776 (SCH 900776)
Labroli, Marc A.,Dwyer, Michael P.,Poker, Cory,Keertikar, Kerry M.,Rossman, Randall,Guzi, Timothy J.
, p. 2601 - 2603 (2016/06/01)
This Letter describes the development of a convergent, efficient route to the CHK1 inhibitor MK-8776. This synthetic approach relies upon the cyclization of a bispyrazole adduct 10 with a optically pure β-keto nitrile 9 to construct the pyrazolo[1,5-a]pyrimidine scaffold in a single step.
Discovery of VTP-27999, an alkyl amine renin inhibitor with potential for clinical utility
Jia, Lanqi,Simpson, Robert D.,Yuan, Jing,Xu, Zhenrong,Zhao, Wei,Cacatian, Salvacion,Tice, Colin M.,Guo, Joan,Ishchenko, Alexey,Singh, Suresh B.,Wu, Zhongren,McKeever, Brian M.,Bukhtiyarov, Yuri,Johnson, Judith A.,Doe, Christopher P.,Harrison, Richard K.,McGeehan, Gerard M.,Dillard, Lawrence W.,Baldwin, John J.,Claremon, David A.
supporting information; experimental part, p. 747 - 751 (2011/12/01)
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)
Renin Inhibitors
-
Page/Page column 46, (2010/12/29)
Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.